alosetron has been researched along with Drug-Related Side Effects and Adverse Reactions in 3 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gastroenterologists and their patients have been affected adversely by removal from the marketplace of two licensed agents for irritable bowel syndrome (IBS): alosetron and tegaserod." | 3.74 | Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. ( Johnson, DA; Schiller, LR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Smith, DA | 1 |
| Schmid, EF | 1 |
| Schiller, LR | 1 |
| Johnson, DA | 1 |
1 review available for alosetron and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Drug withdrawals and the lessons within.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Colitis, Ischemic; Drug Design; Drug-R | 2006 |
2 other studies available for alosetron and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Drug Approval; Drug L | 2008 |